Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could personalize emergency treatment for deadly aortic tears

NCT ID NCT07382375

Disease control Sponsor: Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using artificial intelligence to guide anti-inflammatory treatment can improve outcomes for people with acute aortic dissection, a life-threatening tear in the aorta. Researchers will enroll 300 adults undergoing emergency surgery and randomly assign them to receive either AI-personalized therapy or standard care. The goal is to see if the AI approach reduces organ failure and other complications within the first week after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2027

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Confirmed diagnosis of acute aortic dissection by contrast-enhanced Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA); 2. Planned emergency surgical treatment (including open surgery and endovascular repair); 3. Aged 18-80 years old, regardless of gender; 4. Time from onset to hospital admission ≤ 72 hours; 5. Signed informed consent form by the patient or their authorized agent, with willingness to cooperate with the follow-up of the study. Exclusion Criteria: 1. Complicated with underlying diseases that affect immunoinflammatory status, such as severe infections (e.g., sepsis, infective endocarditis), autoimmune diseases, malignant tumors, chronic liver diseases, and chronic kidney diseases (uremic stage); 2. Long-term use of immunosuppressants or glucocorticoids before surgery (continuous use for ≥ 2 weeks); 3. Pregnant or lactating women; 4. Patients with mental disorders or cognitive dysfunction who cannot cooperate with the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic aneurysm and dissection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aortic Dissection familial thoracic aortic aneurysm and aortic dissection Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aortic aneurysm and dissection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital

    Beijing, China

  • Changzhou First People Hospital

    Changzhou, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Nanchang University Second Hospital

    Nanchang, China

  • Shanghai East Hospital

    Shanghai, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, China

  • West China Hospital of Sichuan University

    Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.